Want to see AU:TRP full AI Analyst Report?
Top Page
Tissue Repair Ltd
(Sydney:TRP)
Select Model
Select Model
Rating:43Neutral
Price Target:
AU$0.08
▼(-3.75% Downside)
Action:Reiterated
Date:09/06/26
The score is primarily constrained by weak financial performance (persistent losses, a steep 2026 revenue drop, and continued/increasing cash burn), despite the benefit of a debt-free balance sheet. Technicals are mildly stabilizing but still pressured by a longer-term downtrend (below key moving averages). Valuation does not provide support given the negative P/E and no dividend yield.
Positive Factors
Debt-Free Balance Sheet
The absence of debt reduces interest obligations and refinancing exposure, giving Tissue Repair greater financial flexibility than a similarly loss-making company with leverage. This can help preserve resources for research, operations, and future strategic funding decisions over the coming quarters.
Negative Factors
Persistent Losses
Recurring losses indicate that the operating model has not yet reached economic viability and remains dependent on external funding rather than internally generated earnings. Continued negative margins also reduce the company’s ability to reinvest, absorb setbacks, or finance growth without diluting shareholders.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-Free Balance Sheet
The absence of debt reduces interest obligations and refinancing exposure, giving Tissue Repair greater financial flexibility than a similarly loss-making company with leverage. This can help preserve resources for research, operations, and future strategic funding decisions over the coming quarters.
Read all positive factors
Tissue Repair Ltd (TRP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$4.84M
Dividend YieldN/A
Average Volume (3M)80.76K
Price to Earnings (P/E)―
Beta (1Y)0.99
Revenue Growth32.22%
EPS Growth-26.53%
CountryAU
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding60,464,844
10 Day Avg. Volume128,898
30 Day Avg. Volume80,758
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)0.69
Price to Sales (P/S)10.80
P/FCF Ratio-0.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tissue Repair Ltd Business Overview & Revenue Model
Company Description
Tissue Repair Ltd (TRP.AX) is an Australian clinical-stage biopharmaceutical firm dedicated to pioneering advanced solutions for wound care. The company's primary focus lies in developing treatments for persistent chronic wounds and enhancing reco...
Tissue Repair Ltd Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
66
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.28M | 559.70K | 2.63M | 152.24K | 3.08K | 171.92K |
| Gross Profit | 1.98M | -1.80M | 2.63M | 150.51K | 428.00 | 170.21K |
| EBITDA | -4.81M | -7.98M | -4.72M | -6.51M | -5.14M | -7.01M |
| Net Income | -3.85M | -5.36M | -4.24M | -4.14M | -4.17M | -6.84M |
Balance Sheet | ||||||
| Total Assets | 12.44M | 10.34M | 14.57M | 19.39M | 22.38M | 25.90M |
| Cash, Cash Equivalents and Short-Term Investments | 8.29M | 4.77M | 12.32M | 16.44M | 21.40M | 25.46M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 607.50K | 1.57M | 662.53K | 1.35M | 497.35K | 559.64K |
| Stockholders Equity | 11.83M | 8.77M | 13.91M | 18.04M | 21.88M | 25.34M |
Cash Flow | ||||||
| Free Cash Flow | -5.70M | -7.55M | -4.12M | -4.95M | -4.26M | -3.97M |
| Operating Cash Flow | -5.27M | -7.50M | -3.70M | -4.95M | -4.26M | -3.97M |
| Investing Cash Flow | -432.20K | -43.65K | -421.67K | -3.35K | -2.24K | -3.92K |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 21.36M |
Tissue Repair Ltd Technical Analysis
Negative
0.08
Price Trends
0.09
Negative
0.11
Negative
0.18
Negative
Market Momentum
>-0.01
Positive
34.88
Neutral
9.52
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:TRP, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.09, and below the 200-day MA of 0.18, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 34.88 is Neutral, neither overbought nor oversold. The STOCH value of 9.52 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:TRP.
Tissue Repair Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | AU$2.89B | -22.28 | -16.30% | ― | 555.67% | 49.08% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | AU$13.54M | -2.74 | -164.96% | ― | -4.24% | 33.39% | |
49 Neutral | AU$198.80M | -13.87 | -36.83% | ― | 51.07% | -47.63% | |
47 Neutral | AU$57.47M | -0.65 | -118.74% | ― | 499.47% | 31.20% | |
46 Neutral | AU$6.67M | -7.86 | -45.29% | 9.09% | 290.25% | 92.05% | |
43 Neutral | AU$4.84M | -0.90 | -52.04% | ― | 32.22% | -26.53% |
* Healthcare Sector Average
AU:TRP
Tissue Repair Ltd
0.08
-0.22
-73.33%
AU:ACR
Acrux
0.01
>-0.01
-21.43%
AU:MSB
Mesoblast Limited
2.29
0.05
2.23%
AU:OCC
Orthocell Ltd
0.73
-0.41
-35.96%
AU:CMB
Regeneus Ltd.
0.46
-0.05
-10.68%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.11
-84.44%
Tissue Repair Ltd Corporate Events
Tissue Repair Brings TR Pro+ Distribution Back In-House in Australasia
Sep 2, 2026
Tissue Repair Limited has resumed direct distribution and management of its TR Pro+® hydrogel in the aesthetic market across Australia and New Zealand, bringing these activities back in-house to sit alongside its existing direct distribution ...
Tissue Repair Limited Confirms ASX-Aligned Governance for 2026
Aug 31, 2026
Tissue Repair Limited, an ASX-listed healthcare company focused on tissue repair solutions, operates under Australia’s corporate governance regime and provides investors with structured oversight of its board and management. The business mai...
Tissue Repair Widens Annual Loss as Net Tangible Assets Decline
Aug 31, 2026
Tissue Repair Ltd reported a marginal 0.4% decline in revenue to $3.21 million for the year ended 30 June 2026, while its net loss widened by 26.5% to $5.36 million, underscoring ongoing profitability challenges despite relatively stable top-line ...
Tissue Repair Plans ASX Delisting and $1m Share Buy-Back
Aug 17, 2026
Biotechnology developer Tissue Repair Ltd, which specialises in second-generation wound healing therapies, is progressing a pipeline led by its Phase 3 chronic wound candidate TR987 and supported by post-procedure gel TR Pro+ and other acute wound...
Tissue Repair Advances Wound Care Trials and Strengthens Cash Position Ahead of Key Regulatory Milestones
Jul 31, 2026
Tissue Repair Ltd reported strong operational progress in the June 2026 quarter, highlighting its U.S. Phase III chronic wound trial, where about 100 patients have been randomised and recruitment continues. The company remains on track to file a U...
Tissue Repair Moves to Delist from ASX Amid Low Liquidity and High Costs
Jul 22, 2026
Tissue Repair Limited has applied to be removed from the Australian Securities Exchange official list under ASX Listing Rule 17.11, following in-principle advice from the exchange that it is likely to agree subject to shareholder approval and a mi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.